Height, Nevus Count, and Melanoma Risk: What Large Cohort Data Shows
When assessing personal risk for cutaneous malignant melanoma, public health discussions usually center on ultraviolet light exposure, blistering sunburns, and genetic family history. Yet epidemiological researchers have also identified less obvious physical characteristics that track with skin cancer rates, including body height. To understand whether stature directly increases risk or simply reflects other biological markers, investigators analyzed prospective data from two enormous female population cohorts.
Study Overview and Cohort Architecture
The investigation, published as a Journal of the American Academy of Dermatology report on height, nevus count, and melanoma risk, evaluated prospective health information collected from white female participants enrolled in the Nurses' Health Study (NHS) and the Nurses' Health Study 2 (NHS2). By following these two groups over extended periods, researchers could observe who developed melanoma over time while accounting for baseline characteristics.
To analyze the relationships accurately, the study included:
- 82,468 women from the Nurses' Health Study.
- 106,069 women from the Nurses' Health Study 2.
The researchers used Cox proportional hazards regression alongside multinomial logistic regression to calculate risk estimates. These models were adjusted for potential confounding variables in multivariate analyses to ensure that other factors were not skewing the observed correlations between height, moles, and skin cancer.
The Documented Link Between Stature and Melanoma
Prior medical literature had established that taller individuals experience elevated rates of melanoma, but the biological basis remained an open question. In this study, every 10-cm increase in physical height corresponded to a hazard ratio of 1.21 (with a 95% confidence interval of 1.12-1.31) for developing cutaneous malignant melanoma. In epidemiological terms, a hazard ratio above 1.0 demonstrates an elevated statistical risk across the cohort for taller individuals compared to their shorter peers.
Because physical height is determined by a complex mix of genetics, developmental factors, and total body surface area, researchers wanted to test what specific intermediate biological trait accounted for this excess vulnerability. That inquiry pointed directly to melanocytic nevi, commonly known as moles.
How Nevus Count Explains the Height Association
Melanocytic nevi represent benign proliferation of pigment-producing cells, and total mole count has long been recognized as a strong indicator of melanoma susceptibility. The prospective JAAD cohort investigation examined whether taller women simply develop more moles, and if those moles account for the heightened disease rate.
When comparing participants who had greater than or equal to 10 moles to women with no nevi, the odds ratios associated with each 10-cm increase in height were:
- An odds ratio of 1.35 (95% confidence interval 1.23-1.48) in the Nurses' Health Study.
- An odds ratio of 1.12 (95% confidence interval 1.09-1.15) in the Nurses' Health Study 2.
Through statistical mediation modeling, the study estimated how much of the height-melanoma correlation was mediated by nevus count. Nevi explained 8.03% of the excess melanoma risk associated with each 10-cm height increase in the NHS cohort, and 10.22% of that excess risk in the NHS2 cohort. The researchers concluded that nevus count is an important explanatory factor for the excess risk seen in taller white women.
Methodological Limits and Study Boundaries
While the study provides powerful observational insights due to its massive participant base, several design limitations must be kept in mind to avoid overstating the results. Both height and mole counts were self-reported by the participants on questionnaires rather than counted during standardized clinical examinations. Furthermore, nevus counts were not full-body tallies; assessments were restricted to counting moles on either 1 arm or both legs.
The study was also limited to white women participating in professional health cohorts. Consequently, these findings describe statistical correlations within a specific demographic rather than a universal biological rule applicable across all skin types or genders. Taller stature is a risk marker, not a modifiable cause of disease.
Practical Skin Surveillance and Tanning Caveats
For individuals reviewing their personal risk profile, these findings underscore that having numerous moles warrants disciplined surveillance. Dermatologists frequently recommend learning the ABCDE mole check method to spot suspicious asymmetry, irregular borders, uneven colors, widening diameters, or physical changes over time.
This evidence is particularly relevant for consumers exploring unlicensed tanning products. Injectable peptides like melanotan I and melanotan II—frequently marketed online without regulatory clearance or manufacturing oversight—actively stimulate melanogenesis throughout the body. Using unregulated tanning peptides can cause rapid darkening, enlargement, or alteration of existing nevi, making routine monitoring for atypical mole changes and melanoma risks substantially more difficult. Anyone with a high mole count, regardless of height, should prioritize standard photoprotection and schedule comprehensive full-body examinations with a board-certified dermatologist.
Sources
Published October 31, 2026. Sources are linked in the text. See our Medical Disclaimer.